- likes
- 282
- comments
- 8
Post
Today at the American College of Rheumatology Convergence, Amgen announced late-breaking positive results from a Phase 3 study exploring its investigational CD40L antagonist fusion protein in patients with Sjögren’s disease. Sjögren’s disease is a heterogeneous autoimmune disease in which people can experience persistent dryness, fatigue and pain, often alongside systemic involvement that can be progressive and affect daily life. We look forward to connecting with the rheumatology community to discuss these results and the ongoing needs of people living with the disease. Learn more: https://amgen.ly/4BWqWqw #ACR26